Oncotelic Therapeutics Reports $2.2 Million Net Loss in Q1 2026, Increases Operating Expenses

Oncotelic Therapeutics, Inc. reported a net loss of approximately $2.2 million for the first quarter of 2026, a significant increase from the $364,264 loss recorded in the same period of 2025. The company's total operating expenses surged to $1.85 million, up from $101,100 year-over-year, primarily driven by a rise in general and administrative expenses, which increased by $1.75 million due to higher stock-based compensation. Research and development expenses saw a modest increase, reflecting the ongoing transition of costs to the joint venture (JV) with GMP Bio, which has taken over the majority of the drug development responsibilities.

As of March 31, 2026, Oncotelic's total assets stood at approximately $394 million, with stockholders' equity reported at $263.3 million, a slight increase from $262.8 million at the end of 2025. The company had cash and cash equivalents of $63.6 million, down from $88.9 million at the end of the previous fiscal year. The working capital deficit was approximately $16.3 million, which includes a contingent liability of $2.6 million related to the issuance of common shares to PointR shareholders upon achieving certain milestones.

Strategically, Oncotelic has made significant advancements through its joint venture with GMP Bio, focusing on the development of OT-101, an immuno-oncology therapeutic. The JV has initiated Phase 2 and Phase 3 clinical trials for OT-101 in high-grade glioma and pancreatic cancer, and has developed a nanoparticle platform aimed at enhancing drug delivery. The company is also exploring additional therapeutic candidates and has established a GMP manufacturing facility in San Diego, California, which is expected to support the production of clinical trial materials.

Looking ahead, Oncotelic's management has expressed optimism about the potential for future growth, particularly with the anticipated initial public offering of the JV in Hong Kong. However, the company acknowledges the need for additional capital to fund ongoing operations and development efforts. The management plans to continue evaluating options for raising funds, including equity and debt financing, to support its product pipeline and operational needs. The company remains committed to enhancing its internal controls and governance structures to address identified weaknesses in its financial reporting processes.